Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Dr. Tap on the Rise of Precision Medicine in Sarcoma

October 30th 2020

William D. Tap, MD, discusses the rise of precision medicine in sarcoma.

Dr. D’Amato on the Importance of Multidisciplinary Care in Sarcoma

October 30th 2020

Gina Z. D'Amato, MD, discusses the importance of multidisciplinary care in sarcoma.

Dr. Atkins on the Expanding Role of Immunotherapy in Oncology

October 30th 2020

Michael B. Atkins, MD, discusses the expanding role of immunotherapy in oncology.

Dr. Tap on the Importance of Community and Academic Collaboration in Sarcoma

October 30th 2020

William D. Tap, MD, discusses the importance of community and academic collaboration in sarcoma.

Dr. Tseng on the Goal of the TARPSWG Analysis in Retroperitoneal Sarcoma

October 27th 2020

William W. Tseng, MD, discusses the goals of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group analysis in retroperitoneal sarcoma.

Dr. Tap on the Evolution of Precision Medicine in Soft Tissue Sarcomas

October 27th 2020

William D. Tap, MD, discusses the evolution of precision medicine in soft tissue sarcomas.

Dr. Atkins on the Impact of Georgetown Lombardi Cancer Center Consortium on Sarcoma Treatment

October 26th 2020

Michael B. Atkins, MD, discusses the impact of the Georgetown Lombardi Cancer Center Consortium on the treatment of patients with sarcoma.

Dr. Atkins on the Importance of the Georgetown Lombardi Cancer Center Consortium

October 26th 2020

Michael B. Atkins, MD, discusses the importance of the Georgetown Lombardi Cancer Center Consortium.

Dr. Gronchi on the Results of the TRASTS Trial in Soft Tissue Sarcoma

October 23rd 2020

Alessandro Gronchi, MD, discusses the results of the phase 2 TRASTS trial in soft tissue sarcoma.

Randall Reflects on Breadth of Sarcoma Data and Beyond at MSTS Meeting

October 23rd 2020

R. Lor Randall, MD, FACS, highlights the various data presented at the annual MSTS meeting and their implications for the future of sarcoma treatment.

Dr. Schwartz on the Benefit of Dose Reduced Nivolumab/Ipilimumab in Metastatic Sarcomas

October 22nd 2020

Gary K. Schwartz, MD, discusses the benefit of dose reducing ipilimumab plus nivolumab in metastatic sarcomas.

Fourth-Line Ripretinib Elicits Significant Responses in Advanced GIST

October 22nd 2020

César Serrano-García, MD, PhD, highlights ripretinib and the meaningful benefit it provides as a fourth- and later-line therapy in patients with advanced gastrointestinal stromal tumor who harbor KIT or PDGFRA mutations.

Dr. Abraham on Remaining Questions With Pexidartinib in TGCT

October 21st 2020

John A. Abraham, MD, FACS, discusses remaining questions with pexidartinib in tenosynovial giant cell tumor.

Dr. D’Amato on the Limitations of Liquid Biopsy in Sarcoma

October 21st 2020

Gina Z. D'Amato, MD, discusses the limitations of liquid biopsy in sarcoma.

Dr. Maki on the Utility of IDH1/2 Inhibitors in Chondrosarcoma

October 21st 2020

Robert G. Maki, MD, PhD, FACP, FASCO, discusses the utility of IDH1/2 inhibitors in chondrosarcoma.

Dr. Abraham on the Clinical Utility of Pexidartinib in TGCT

October 20th 2020

John A. Abraham, MD, FACS, discusses the clinical utility of pexidartinib in tenosynovial giant cell tumor.

Ripretinib Continues to Showcase Clinically Meaningful Benefit, Safety in Advanced GIST

October 19th 2020

Ripretinib continues to show clinically meaningful benefit with an acceptable safety profile when used as a fourth- or later-line treatment for patients with advanced gastrointestinal stromal tumor.

Dr. Maki on the Utility of Tazemetostat in Epithelioid Sarcoma

October 19th 2020

Robert G. Maki, MD, PhD, FACP, FASCO, discusses the utility of tazemetostat in epithelioid sarcoma.

Pediatric Osteosarcoma Harbors a High Incidence of Pathogenic TP53 Variants

October 19th 2020

TP53 was found to be the only gene with a germline de novo pathogenic or likely pathogenic variant in pediatric patients with osteosarcoma.

Dr. Pautier on Results of the LMS-02 Trial in Uterine and Soft Tissue Sarcomas

October 16th 2020

Patricia Pautier, MD, discusses the results of the phase 2 LMS-02 trial with doxorubicin and trabectedin in uterine and soft tissue leiomyosarcoma.